Playing for high stakes
According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with a…
Author
TC Biopharm to start phase II/III studies of ImmuniCell in October
Currently focused on skin, renal and lung cancer, the platform has potential to treat all types of cancer tumours as well as viral…
Mylan’s One Quality Standard a long way off
Some industry observers are surprised that ‘significant violations’ of this nature have not warranted an import alert or ban
Getting the science right
The ‘no pain, no gain’ mantra seems to be finally putting the $25 billion AstraZeneca on the road to recovery, as it continues to…
New strategies for growth
After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint glimmers of…
Digital India: A new game needs new rules
With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement with technology
BI’s afatinib LUX-Lung 8 trial data released at ASCO 2015
Patients from 23 countries, including India, participated in the trial, which is reportedly the first prospective trial to…
Lee Pharma revives the CL debate
With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to…
TRIPs-ing time again
When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to plug…
Data integrity … dil se
Two reports, released in early June, have both good news and bad news for the pharma industry in India